Amgen Inc. (AMGN) Tumbled To Nearly A 4-Month Low On Drug Safety Concerns

Amgen Inc. (AMGN) and UCB announced Sunday that the EVENITY (romosozumab) ARCH study met both primary endpoints and the key secondary endpoint.

from RTT - Before the Bell http://ift.tt/2rOBq7K
via IFTTT